$10.55
0.19[1.83%]
At close: Apr 19
$10.55
0[0.00%]
After Hours: 7:52PM EDT
Roivant Sciences
(NASDAQ:ROIV)Latest News for Roivant Sciences Stock (NASDAQ:ROIV)
Roivant Sciences Stock (NASDAQ: ROIV)
Categories: All
Wednesday, April 03, 2024
- Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18Benzinga Newsdesk - Apr 3, 2024, 11:18AM
- HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $18Benzinga Newsdesk - Apr 3, 2024, 7:05AM
- Deutsche Bank Maintains Buy on Roivant Sciences, Raises Price Target to $15Benzinga Newsdesk - Apr 3, 2024, 5:14AM
Tuesday, April 02, 2024
- Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage StudyVandana Singh - Apr 2, 2024, 12:31PM
- Roivant Sciences shares are trading higher after the company announced results from its NEPTUNE Phase 2 study of brepocitinib. The company's board also authorized a share repurchase program of up to $1.5 billion, including the repurchase of all 71.3 million shares held by Sumitomo Pharma.Benzinga Newsdesk - Apr 2, 2024, 7:28AM
- Roivant Sciences Reveals Board Authorization For Up To $1.5B Share Repurchase Program, Including Repurchase Of Entire Sumitomo Pharma Stake For $648MBenzinga Newsdesk - Apr 2, 2024, 7:12AM
- Roivant Announces Positive NEPTUNE Study Results For Brepocitinib In Non-infectious UveitisBenzinga Newsdesk - Apr 2, 2024, 7:10AM
Friday, March 29, 2024
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Monday, March 25, 2024
Monday, February 19, 2024
Thursday, February 15, 2024
Wednesday, February 14, 2024
Tuesday, February 13, 2024
Monday, February 12, 2024
Wednesday, January 10, 2024
Friday, January 05, 2024
Tuesday, January 02, 2024
Thursday, December 21, 2023
- Roivant shares are trading higher after Immunovant announced results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.Benzinga Newsdesk - Dec 21, 2023, 9:13AM
- Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%Vandana Singh - Dec 21, 2023, 8:57AM
Wednesday, December 20, 2023
- Immunovant Says Results From Initial Cohort Of Patients In An Ongoing 24-week Phase 2 Clinical Trial Of Batoclimab In Patients With Graves' Disease Meaningfully Exceeded 50% Response RatesBenzinga Newsdesk - Dec 20, 2023, 4:32PM
- FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionAvi Kapoor - Dec 20, 2023, 5:33AM
Tuesday, December 12, 2023
Tuesday, November 28, 2023
Monday, November 27, 2023
- Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?Vandana Singh - Nov 27, 2023, 12:32PM
- Roivant Sciences shares are trading lower after the company announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint.Benzinga Newsdesk - Nov 27, 2023, 9:55AM
- Roivant And Priovant's Phase 2 Study Of Oral Brepocitinib In Systemic Lupus Erythematosus Failed To Meet Its Primary Endpoint Of Systemic Lupus Erythematosus Responder Index Change Of 4 At Week 52Benzinga Newsdesk - Nov 27, 2023, 8:08AM
Wednesday, November 15, 2023
Tuesday, November 14, 2023
Monday, November 13, 2023
- Roivant Looks Forward To Announcing Additional Clinical Results For 1402 And brepocitinib In The Final Quarter Of Calendar YearBenzinga Newsdesk - Nov 13, 2023, 7:12AM
- Roivant Sciences Q2 EPS $(0.40) Vs. $(0.42) Last Year, Sales $37.10M Beat $29.39M EstimateBenzinga Newsdesk - Nov 13, 2023, 7:02AM
- Earnings Scheduled For November 13, 2023Benzinga Insights - Nov 13, 2023, 6:40AM
Friday, November 10, 2023
Monday, October 23, 2023
- Roviant Sciences shares are trading lower, reversing from earlier strength after the company announced it sold its 75% stake in Telavant to Roche.Benzinga Newsdesk - Oct 23, 2023, 1:11PM
- Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B DealLekha Gupta - Oct 23, 2023, 8:55AM
- Roviant shares are trading higher after the company sold its 75% stake in Telavant to Roche. Roche to pay $7.1B for Telavant which Roivant owns 75% of.Luke J Jacobi - Oct 23, 2023, 8:19AM
- Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving PremarketLisa Levin - Oct 23, 2023, 7:32AM
- Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market SessionLisa Levin - Oct 23, 2023, 5:53AM
- Roche Agrees To Acquire Telavant, Including Rights To Novel TL1A-Directed Antibody (RVT-3101), From Roivant Tor $7.1BBenzinga Newsdesk - Oct 23, 2023, 1:45AM